Zacks Research Comments on Qiagen’s Q3 Earnings (NYSE:QGEN)

Qiagen N.V. (NYSE:QGEN) – Investment analysts at Zacks Research reduced their Q3 2026 earnings estimates for shares of Qiagen in a research report issued to clients and investors on Wednesday, August 26th. Zacks Research analyst Team now expects that the company will post earnings of $0.62 per share for the quarter, down from their previous estimate of $0.63. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Qiagen’s current full-year earnings is $2.43 per share. Zacks Research also issued estimates for Qiagen’s Q4 2026 earnings at $0.64 EPS, FY2026 earnings at $2.43 EPS, Q1 2027 earnings at $0.56 EPS, Q2 2027 earnings at $0.65 EPS, Q3 2027 earnings at $0.67 EPS, Q4 2027 earnings at $0.73 EPS, FY2027 earnings at $2.60 EPS, Q1 2028 earnings at $0.68 EPS, Q2 2028 earnings at $0.72 EPS and FY2028 earnings at $2.91 EPS.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The firm had revenue of $535.04 million during the quarter, compared to analysts’ expectations of $527.50 million. During the same period last year, the business earned $0.60 earnings per share. Qiagen’s revenue was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS.

Other equities research analysts have also recently issued reports about the stock. Jefferies Financial Group reiterated a “buy” rating and set a $48.00 price target on shares of Qiagen in a research report on Thursday, August 6th. Stifel Nicolaus set a $40.00 target price on shares of Qiagen in a research note on Friday, August 7th. Berenberg Bank set a $45.50 target price on shares of Qiagen and gave the stock a “hold” rating in a report on Tuesday, July 14th. Kepler Capital Markets set a $38.60 price target on shares of Qiagen and gave the company a “hold” rating in a research report on Thursday, June 25th. Finally, Morgan Stanley upgraded shares of Qiagen from an “overweight” rating to an “overweight” rating and boosted their price target for the stock from $40.00 to $42.00 in a research note on Tuesday, June 23rd. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $43.93.

Qiagen Price Performance

QGEN stock opened at $43.32 on Thursday. The business has a fifty day moving average of $41.11 and a two-hundred day moving average of $40.70. The company has a quick ratio of 2.31, a current ratio of 2.85 and a debt-to-equity ratio of 0.48. The stock has a market cap of $8.93 billion, a price-to-earnings ratio of 22.20, a price-to-earnings-growth ratio of 4.35 and a beta of 0.63. Qiagen has a 52-week low of $32.53 and a 52-week high of $57.81.

Institutional Trading of Qiagen

Several hedge funds have recently added to or reduced their stakes in QGEN. Danske Bank A S acquired a new position in Qiagen during the 3rd quarter worth approximately $36,000. Manchester Capital Management LLC acquired a new stake in shares of Qiagen in the 4th quarter valued at $42,000. Hilltop National Bank purchased a new stake in shares of Qiagen during the 2nd quarter worth $50,000. Global Retirement Partners LLC lifted its position in shares of Qiagen by 279.9% during the 4th quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock worth $52,000 after purchasing an additional 851 shares during the last quarter. Finally, Advisory Services Network LLC acquired a new position in shares of Qiagen during the third quarter worth $64,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Key Stories Impacting Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Zacks Research raised its FY2028 EPS estimate to $2.91 from $2.88 and increased forecasts for Q2 2027, Q1 2028, Q2 2028 and Q4 2027. These revisions suggest some improvement in Qiagen’s longer-term earnings outlook.
• Positive Sentiment: Two potential buyers have reportedly begun formal due diligence in Qiagen’s sales process. Although no transaction is assured, the development could support takeover speculation and provide a potential catalyst for QGEN shares. Two potential buyers begin formal due diligence in Qiagen sales process
• Neutral Sentiment: Qiagen appointed Jonathan Pratt as chief executive officer. The leadership change may influence strategy, but investors will likely need more information on his priorities and execution plans before assigning a clear valuation impact. Qiagen appoints Jonathan Pratt as CEO
• Negative Sentiment: Zacks Research made several small downward revisions, lowering its FY2026 EPS estimate to $2.43 from $2.44, FY2027 to $2.60 from $2.63, Q1 2027 to $0.56 from $0.60, Q3 2026 to $0.62 from $0.63 and Q4 2026 to $0.64 from $0.65. The cuts point to somewhat softer near-term earnings expectations.
• Negative Sentiment: Zacks maintains a “Hold” rating on QGEN. The absence of a bullish rating change may limit enthusiasm despite the modest increases to some longer-term estimates.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.